https://orcid.org/0000-0002-2542-6011
References
- PunekarYS, MullerovaH, SmallM, et al. Prevalence and burden of dyspnoea among patients with chronic obstructive pulmonary disease in five European countries. Pulm Ther. 2016;2(1):59–72. doi:10.1007/s41030-016-0011-5
- KesslerR, PartridgeMR, MiravitllesM, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J. 2011;37(2):264–272. doi:10.1183/09031936.0005111021115606
- GruenbergerJ-B, VietriJ, KeiningerDL, MahlerDA. Greater dyspnea is associated with lower health-related quality of life among European patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:937–944. doi:10.2147/COPD.S12374428360517
- BannerKH, PressNJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol. 2009;157(6):892–906. doi:10.1111/j.1476-5381.2009.00170.x19508401
- de BoerJ, PhilpottAJ, van AmsterdamRG, ShahidM, ZaagsmaJ, NicholsonCD. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br J Pharmacol. 1992;106(4):1028–1034. doi:10.1111/j.1476-5381.1992.tb14451.x1393276
- PageCP, SpinaD. Phosphodiesterase inhibitors in the treatment of inflammatory diseases FrancisS, ContiM, HouslayM, editors. In Phosphodiesterases as Drug Targets. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer; 2011 391–414. http://link.springer.com/10.1007/978-3-642-17969-3_17.: AccessedAugust 31, 2020.
- FranciosiLG, DiamantZ, BannerKH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727. doi:10.1016/S2213-2600(13)70187-524429275
- SinghD, Abbott-BannerK, BengtssonT, NewmanK. The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD. Eur Respir J. 2018;52(5):1801074. doi:10.1183/13993003.01074-201830166326
- BjermerL, Abbott-BannerK, NewmanK. Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma. Pulm Pharmacol Ther. 2019;58:101814. doi:10.1016/J.PUPT.2019.10181431202957
- SinghD, Abbott-BannerKH, ReidF, NewmanK, PhaseA. I, randomised, double blind, placebo controlled, study to assess the safety, tolerability and pharmacokinetics of multiple inhaled doses of RPL554 administered by nebuliser to healthy male subjects and stable COPD patients. Am J Respir Crit Care Med. 2016;193:A6838.
- SinghD, MartinezFJ, WatzH, BengtssonT, MaurerBT. A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD. Respir Res. 2020;21(1):47. doi:10.1186/s12931-020-1307-432041601
- LeidyNK, MurrayLT, MonzBU, et al. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014;15(1):124. doi:10.1186/s12931-014-0124-z25287629
- MahlerDA, WitekTJ. The MCID of the Transition Dyspnea Index is a total score of one unit. COPD. 2005;2(1):99–103. doi:10.1081/COPD-20005066617136969
- JonesPW. St. George’s Respiratory Questionnaire: MCID. COPD. 2005;2(1):75–79. doi:10.1081/COPD-20005051317136966
- JansonC, MarksG, BuistS, et al. The impact of COPD on health status: findings from the BOLD study. Eur Respir J. 2013;42(6):1472–1483. doi:10.1183/09031936.0015371223722617
- PunekarYS, WurstK, ShuklaA. Resource use and costs up to two years post diagnosis among newly diagnosed COPD patients in the UK primary care setting: A retrospective cohort study. COPD J Chronic Obstr Pulm Dis. 2015;12(3):267–275. doi:10.3109/15412555.2014.933953
- JonesPW, LeidyNK, HareendranA, LamarcaR, ChuecosF, Garcia GilE. The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies. Respir Res. 2016;17(1):61. doi:10.1186/s12931-016-0372-127215749
- MartinezFJ, CalverleyPMA, GoehringU-M, BroseM, FabbriLM, RabeKF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385(9971):857–866. doi:10.1016/S0140-6736(14)62410-725684586
- MartinezFJ, RabeKF, SethiS, et al. Effect of roflumilast and inhaled corticosteroid/long-acting β2-agonist on chronic obstructive pulmonary disease exacerbations (RE2SPOND). A randomized clinical trial. Am J Respir Crit Care Med. 2016;194(5):559–567. doi:10.1164/rccm.201607-1349OC27585384